SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sunesis Pharmaceuticals (SNSS) -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (15)12/11/2006 12:20:02 PM
From: tuck  Respond to of 48
 
Interesting, because the same investigator did the KOS-1022 trial in about the same population of patients. KOS-1022 saw actual responses, whereas SNS-595 merely got reduction in blast counts.

Message 23090068

The abstracts have been available for a while, so I suppose I shouldn't read too much into today's market reaction to the PRs, but KOSN is down some, and SNSS is steady. Haven't looked at SNSS chart recently, though.

Cheers, Tuck